All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for KYVERNA THERAPEUTICS, INC. · Biopharmaceutical company focused on developing cell therapies for autoimmune diseases.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $60,000.00 income · posted Apr 20, 2026

Official filing document

Lobbying activity 1

Health Issues

Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to appropriations report language for Fiscal Year 2027.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.